TD: Tardive Dyskinesia for total (+) active metabolites for tetrabenazine & deutetrabenazine Schneider et al (2021) Adapted from Diana (2007), Schneider et al (2021) & Cheung & Parmar (2022) Notes on Reserpine & Synaptic vesicles:
Combining it with another GLP-1 or GIP agonist (semaglutide, tirzepatide) would compound the same receptor load and the same GI and hypoglycemia risks with no efficacy evidence to support it
Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S , Maru D
Consider which protocol you can realistically maintain long-term, as consistency determines outcomes with either compound